Previous Close | 18.54 |
Open | 18.46 |
Bid | 0.00 x 1400 |
Ask | 0.00 x 1000 |
Day's Range | 18.31 - 19.53 |
52 Week Range | 17.81 - 37.86 |
Volume | |
Avg. Volume | 296,064 |
Market Cap | 375.473M |
Beta (5Y Monthly) | 0.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.70 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 70.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALBO
We feel now is a pretty good time to analyse Albireo Pharma, Inc.'s ( NASDAQ:ALBO ) business as it appears the company...
Four presentations highlight newest data from landmark Phase 3 PEDFIC 1 and PEDFIC 2 trials, largest studies completed in PFICNew analysis show potential for greater response and higher proportion of pruritus responders with dose escalation and consistent tolerability across dosesLong-term data provide evidence of consistent improvements in hepatic parameters, growth, sleep, and biomarkers in patients with all PFIC types with treatment up to 72 weeks BOSTON, June 24, 2022 (GLOBE NEWSWIRE) -- Alb
New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parametersLong-term data from PEDFIC trials of Bylvay show dramatic quality of life deficits in patients and families affected by PFICStudies show consistent and sustained efficacy for Bylvay across all PFIC types Announces new SPARK Grants Program, accepting applications for projects to improve care for rare